Humanigen Says Marketing Authorization Submission For Lenzilumab Accepted In UK For Covid Treatment

(RTTNews) - Humanigen, Inc. (HGEN) on Friday said its marketing authorization submission for lenzilumab for the treatment of COVID-19 has been accepted by the Medicines and Healthcare Products Regulatory Agency of UK for expedited COVID-related rolling review.

Humanigen said the assessment is expected to be faster than a standard rolling review.

"In the event Emergency Use Authorization in the United States and Marketing Authorization in the UK are awarded concurrently or in parallel, we will work with the relevant authorities to ensure appropriate allocation of lenzilumab in each country," said Timothy E. Morris, COO and CFO of Humanigen.